Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02740894
  4. Details
NCT02740894 Clinical Trial

Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ? Clinical Trial

Official title:
Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02740894
Other study ID # 2016-02-006CC
Secondary ID
Status Completed
Phase N/A
First received April 5, 2016
Last updated April 12, 2016
Start date February 2016
Est. completion date April 2016

Study information
Verified date April 2016
Source Taipei Veterans General Hospital, Taiwan
Contact n/a
Is FDA regulated No
Health authority Taiwan: Taipei Veterans General Hospital
Study type Observational

Clinical Trial Summary

Not significantly increased survival in T/T

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- NSCLC with spinal metastasis

Exclusion Criteria:

- brain metastasis and expected survival < 3 months

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Intervention

Drug:
• Gefitinib

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Outcome
Type Measure Description Time frame Safety issue
Primary Survival and neurologic outcome of 60 participants receiving targeted therapy for nonsmall cell lung cancer with spinal metastaasis. Neurological outcome by Frankel grading and ambulation status. postoperation to mortality, up to 2 year Yes